A detailed history of Platinum Investment Management LTD transactions in Immunovant, Inc. stock. As of the latest transaction made, Platinum Investment Management LTD holds 192,242 shares of IMVT stock, worth $5.29 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
192,242
Previous 190,656 0.83%
Holding current value
$5.29 Million
Previous $6.16 Million 17.61%
% of portfolio
0.21%
Previous 0.25%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$25.1 - $31.61 $39,808 - $50,133
1,586 Added 0.83%
192,242 $5.08 Million
Q1 2024

May 13, 2024

SELL
$30.27 - $43.79 $1.15 Million - $1.67 Million
-38,109 Reduced 16.66%
190,656 $6.16 Million
Q4 2023

Feb 13, 2024

BUY
$31.31 - $44.19 $88,482 - $124,880
2,826 Added 1.25%
228,765 $9.64 Million
Q3 2023

Nov 02, 2023

SELL
$18.55 - $39.96 $1.91 Million - $4.11 Million
-102,903 Reduced 31.29%
225,939 $8.67 Million
Q2 2023

Aug 10, 2023

SELL
$14.2 - $23.75 $257,417 - $430,540
-18,128 Reduced 5.22%
328,842 $6.24 Million
Q1 2023

May 11, 2023

SELL
$15.27 - $19.72 $982,273 - $1.27 Million
-64,327 Reduced 15.64%
346,970 $5.38 Million
Q4 2022

Feb 13, 2023

SELL
$6.59 - $17.75 $1.63 Million - $4.4 Million
-247,778 Reduced 37.59%
411,297 $7.3 Million
Q3 2022

Nov 14, 2022

SELL
$3.93 - $6.37 $465,763 - $754,940
-118,515 Reduced 15.24%
659,075 $3.68 Million
Q2 2022

Aug 11, 2022

BUY
$3.38 - $5.65 $307,343 - $513,754
90,930 Added 13.24%
777,590 $3.03 Million
Q1 2022

May 13, 2022

BUY
$5.06 - $8.77 $358,045 - $620,565
70,760 Added 11.49%
686,660 $3.78 Million
Q4 2021

Feb 11, 2022

BUY
$7.33 - $9.32 $445,920 - $566,982
60,835 Added 10.96%
615,900 $5.25 Million
Q3 2021

Nov 09, 2021

BUY
$7.01 - $11.37 $3.89 Million - $6.31 Million
555,065 New
555,065 $4.82 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Platinum Investment Management LTD Portfolio

Follow Platinum Investment Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Platinum Investment Management LTD with notifications on news.